Hepatocellular adenomas: Current update on genetics, taxonomy, and management

Journal of Computer Assisted Tomography

Volumn 35, Issue 2, 2011, Pages 159-166

  Shanbhogue, Alampady ^a   Shah, Shetal N ^b   Zaheer, Atif ^c   Prasad, Srinivasa R ^a   Takahashi, Naoki ^d   Vikram, Raghunandan ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

computed tomography; genetics; hepatocellular adenoma; magnetic resonance imaging; pathology

Indexed keywords

CHROMOSOMES; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; PATHOLOGY; TAXONOMIES; TUMORS;

'CURRENT; COMPUTED TOMOGRAPHY; CROSS-SECTIONAL IMAGING; GENETIC; HEPATOCELLULAR; HEPATOCELLULAR ADENOMA; ONCOGENESIS;

MAGNETIC RESONANCE IMAGING;

AXIN; BETA CATENIN; ESTROGEN; FATTY ACID BINDING PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; SOMATOMEDIN B RECEPTOR;

ABDOMINAL PAIN; ALCOHOLISM; ARTIFICIAL EMBOLISM; BIOPSY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL FEATURE; COLON POLYPOSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FATTY LIVER; GENE ACTIVATION; GENE ACTIVITY; GENE MUTATION; GENETICS; GLYCOGEN STORAGE DISEASE; HEPATIC ARTERY; HISTOPATHOLOGY; HUMAN; IMAGING; IMMUNOHISTOCHEMISTRY; INFLAMMATORY HEPATOCELLULAR ADENOMA; LIPID STORAGE; LIVER ADENOMA; LIVER ADENOMATOSIS; LIVER CELL; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; TAXONOMY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPPER ABDOMINAL PAIN;

EID: 79953815733     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e31820bad61     Document Type: Review

References (65)

1. Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception. 1991;43:643-652.
2. Nime F, Pickren JW, Vana J, et al. The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer. 1979;44:1481-1489. (Pubitemid 10193397)
3. Staib FKM, Krupp M, Maass T, et al. Comparative genomics analysis of hepatic adenoma, normal liver, and HCC revealed closer relationship of adenoma to HCC with favorable outcome. J Hepatol. 2010;52:S319-S457.
4. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50:481-489.
5. Bioulac-Sage P, Laumonier H, Laurent C, et al. Hepatocellular adenoma: what is new in 2008. Hepatol Int. 2008;2:316-321.
6. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698-1705.
7. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515-524.
8. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg. 2010;27:32-38.
9. Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg. 2004;187:181-191. (Pubitemid 38183430)
10. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976;294:470-472.
11. Scalori A, Tavani A, Gallus S, et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol. 2002;186:195-197. (Pubitemid 34165432)
12. Heinemann LA,Weimann A, Gerken G, et al. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur J Contracept Reprod Health Care. 1998;3:194-200.
13. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46:521-527.
14. Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol. 2001;33:234-236. (Pubitemid 32762897)
15. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Focal nodular hyperplasia, hepatocellular adenomas: past, present, future. Gastroenterol Clin Biol. 2010;34:355-358.
16. Carrasco D, Barrachina M, Prieto M, et al. Clomiphene citrate and liver-cell adenoma. N Engl J Med. 1984;310:1120-1121. (Pubitemid 14131510)
17. Vazquez JJ, Marigil MA. Liver-cell adenoma in an epileptic man on barbiturates. Histol Histopathol. 1989;4:301-303. (Pubitemid 19177947)
18. Zucman-Rossi J. Genetic alterations in hepatocellular adenomas: recent findings and new challenges. J Hepatol. 2004;40:1036-1039. (Pubitemid 38670142)
19. Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg. 2001;136:1033-1038. (Pubitemid 32982993)
20. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg. 1988;208:558-564.
21. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford). 2005;7:186-196. (Pubitemid 41535849)
22. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
23. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology. 2007;46:140-146. (Pubitemid 47171930)
24. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457:200-204.
25. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740-748.
26. Spannbauer MM, Trautwein C. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Hepatology. 2009;49:1387-1389.
27. Tang Y, Kitisin K, Jogunoori W, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A. 2008;105:2445-2450. (Pubitemid 351520533)
28. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409-426. (Pubitemid 37099454)
29. Laumonier H, Bioulac-Sage P, Laurent C, et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008;48:808-818.
30. Laumonier HB-SP, Laurent C, Sa Cunha A, et al. Contrast-enhanced ultra sonography to identify the Two major subtypes of hepatocellular adenoma. J Hepatol. 2010;52:S183-S317.
31. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MOD-1). Nature. 1996;384:458-460. (Pubitemid 26414661)
32. Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1α inactivation. Gastroenterology. 2003;125:1470-1475. (Pubitemid 37409767)
33. Rebouissou S, Imbeaud S, Balabaud C, et al. HNF1α inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282:14437-14446. (Pubitemid 47100455)
34. Shih DQ, Bussen M, Sehayek E, et al. Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet. 2001;27:375-382. (Pubitemid 32268417)
35. Cavalieri E, Frenkel K, Liehr JG, et al. Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000;75-93.
36. Chung KY, Mayo-Smith WW, Saini S, et al. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol. 1995;165:303-308.
37. Ichikawa T, Federle MP, Grazioli L, et al. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology. 2000;214:861-868. (Pubitemid 30115393)
38. Paulson EK, McClellan JS, Washington K, et al. Hepatic adenoma: MR characteristics and correlation with pathologic findings. AJR Am J Roentgenol. 1994;163:113-116. (Pubitemid 24225698)
39. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol. 2002;39:530-535.
40. Longerich T, Schirmacher P. A new link between cancer and inflammation? J Hepatol. 2009;51:230-232.
41. Chen YW, Jeng YM, Yeh SH, et al. P53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology. 2002;36:927-935.
42. Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr. 2002;161(suppl 1):S46-S49.
43. Kishnani PS, Chuang TP, Bali D, et al. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type IA glycogen storage disease. Hum Mol Genet. 2009;18:4781-4790.
44. De Souza AT, Hankins GR, Washington MK, et al. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene. 1995;10:1725-1729.
45. Yamada T, De Souza AT, Finkelstein S, et al. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A. 1997;94:10351-10355. (Pubitemid 27407045)
46. Cassiman D, Libbrecht L, Verslype C, et al. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type IA. J Hepatol. 2010;53:213-217.
47. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology. 1985;89:1132-1138.
48. Lewin M, Handra-Luca A, Arrive L, et al. Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology. 2006;241:433-440. (Pubitemid 44632889)
49. Greaves WO, Bhattacharya B. Hepatic adenomatosis. Arch Pathol Lab Med. 2008;132:1951-1955.
50. Vetelainen R, Erdogan D, de Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int. 2008;28:499-508. (Pubitemid 351411136)
51. Prasad SR, Sahani DV, Mino-Kenudson M, et al. Benign hepatic neoplasms: an update on cross-sectional imaging spectrum. J Comput Assist Tomogr. 2008;32:829-840.
52. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005;236:166-177. (Pubitemid 40853309)
53. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009;44(suppl 19):112-118.
54. Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001;21:877-892; discussion 892-874.
55. Erdogan D, Busch OR, van Delden OM, et al. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int. 2006;26:433-438.
56. Stoot JH, van der Linden E, Terpstra OT, et al. Life-saving therapy for haemorrhaging liver adenomas using selective arterial embolization. Br J Surg. 2007;94:1249-1253. (Pubitemid 47584774)
57. Terkivatan T, de Wilt JH, de Man RA, et al. Treatment of ruptured hepatocellular adenoma. Br J Surg. 2001;88:207-209. (Pubitemid 32142706)
58. Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumours. Dig Surg. 2002;19:109-113. (Pubitemid 34458055)
59. Ribeiro A, Burgart LJ, Nagorney DM, et al. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg. 1998;4:388-398. (Pubitemid 28413240)
60. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg. 2010;27:39-45.
61. Rhim H, Lim HK, Kim YS, et al. Percutaneous radiofrequency ablation of hepatocellular adenoma: initial experience in 10 patients. J Gastroenterol Hepatol. 2008;23:e422-e427.
62. van der Sluis FJ, Bosch JL, Terkivatan T, et al. Hepatocellular adenoma: cost-effectiveness of different treatment strategies. Radiology. 2009;252:737-746.
63. Terkivatan T, de Wilt JH, de Man RA, et al. Management of hepatocellular adenoma during pregnancy. Liver. 2000;20:186-187. (Pubitemid 30219148)
64. van Aalten SM, Terkivatan T, de Man RA, et al. Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences. Dig Surg. 2010;27:61-67.
65. Chiche L, Dao T, Salame E, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg. 2000;231:74-81. (Pubitemid 30043942)